Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Azathioprine
DE Pharmaceuticals
L04AX01
Azathioprine
50mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 08020100
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT IMURAN ® 25MG AND 50MG FILM-COATED TABLETS AZATHIOPRINE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, nurse or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Imuran Tablets are and what they are used for 2. What you need to know before you take Imuran 3. How to take Imuran 4. Possible side effects 5. How to store Imuran 6. Contents of the pack and other information 1. WHAT IMURAN TABLETS ARE AND WHAT THEY ARE USED FOR Imuran tablets contain the active substance azathioprine. They belong to a group of medicines called immunosuppressives. This means that they reduce the strength of your immune system. Imuran Tablets may be used to help your body accept an organ transplant, such as a new kidney, heart or liver, or to treat some diseases where your immune system is reacting against your own body (autoimmune diseases). Autoimmune diseases may include: - severe rheumatoid arthritis (a disease where the immune system attacks cells lining the joints causing swelling, pain, stiffness of the joints), - systemic lupus erythematosus (a disease where the immune system attacks many of the body’s organs and tissues, including skin, joints, kidneys, brain, and other organs causing severe fatigue, fever, stiffness and joint pain), - dermatomyositis and polymyositis (a group of diseases causing inflammation of the muscles, muscle weakness and skin rash), - auto-immune chronic active hepatitis (a disease in which the immune system attacks liver cells causing liver inflammation, fatigue, muscle aches, yello Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Imuran 50mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Azathioprine Each tablet contains 50 mg of the active substance azathioprine. Excipient(s) with known effect Each 50 mg tablet contains 74 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet Yellow, round, biconvex, scored, film-coated tablets, branded ‘IM 5’ The score line is not for breaking the tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Azathioprine is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. Azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated to enhance the survival of organ transplants, such as renal transplants, cardiac transplants, and hepatic transplants. It also reduces the corticosteroid requirements of renal transplant recipients. Azathioprine is indicated for the treatment of moderate to severe inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom corticosteroid therapy is required, in patients who cannot tolerate corticosteroid therapy, or in patients whose disease is refractory to other standard first line therapy. Azathioprine, either alone or more usually in combination with corticosteroids and/or other medicinal products and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: • severe rheumatoid arthritis; • systemic lupus erythematosus; • dermatomyositis and polymyositis; • auto-immune chronic active hepa Read the complete document